Rafi Farber

Lastest Stories by Rafi Farber

A trade war is brewing between the United States and China, but U.S. companies operating in China do not seem to have much to say about the whole matter.
CNN’s thinly veiled threat against an as-of-yet private citizen for criticizing the network in an internet meme is one of the more bizarre and arguably puerile moves a large media organization has...
The Federal Reserve may not be able to shrink its balance sheet in the current environment as much as it wants to, if at all. Here’s why.
With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag.
“Sell in May and go away” echoes are bouncing off the walls this time of year, and it is worth a look where this trend comes from in order to determine where it may be going this year.
The road to a pivotal Phase 3 trial usually takes years following an IPO, but Therapix Biosciences may reach that stage in just a few months' time.
Here are five stocks that have skyrocketed since Donald Trump’s victory, so much so that four of the five are already above their 12-month consensus estimates.
Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even — for many biotech companies in the depression space.
There is no indication that Fiat Chrysler has done anything wrong, but it has other problems that could compound its current hardships with regulators and drive its stock price down even further.
This year the money supply has recovered almost two whole months early, which means we could be heading for an exceptionally strong fourth quarter for stocks.
Lucky for Teva Pharmaceuticals, interest rates on all kinds of debt have never been lower in recorded human history, and they keep getting lower even beyond basic logic.
The fact that major health care mergers were announced at the same time that the Affordable Care Act began to take full effect is no coincidence.
It may come as a shock, but out of the 10 largest investment banks by assets, only one of them has outperformed the S&P 500 since bear market bottom on March 6, 2009.
After all the talk of interest rate hikes and gradually tightening monetary policy from the Federal Reserve, interest rates on the 10-year bond have touched record lows yet again.
The debate between bulls and bears over the general stock market continues on as the S&P 500, Dow Jones and the Nasdaq all have failed to make much headway since February 2015. Stalled bull...